Human medicines European public assessment report (EPAR): LysaKare, arginine,lysine, Date of authorisation: 25/07/2019, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Metalyse, tenecteplase, Date of authorisation: 23/02/2001, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Fetcroja, cefiderocol, Date of authorisation: 23/04/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Accord, eltrombopag, Date of authorisation: 28/03/2025, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Date of authorisation: 20/07/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 59, Status: Authorised

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 22, Status: Authorised